Eflornithine Is Safer than Melarsoprol for the Treatment of Second-Stage Trypanosoma brucei gambiense Human African Trypanosomiasis | Zendy

François Chappuis | Zendy; N. Udayraj | Zendy; K. Stietenroth | Zendy; A. Meussen | Zendy; Patrick Bovier | Zendy

Open Access

Eflornithine Is Safer than Melarsoprol for the Treatment of Second-Stage Trypanosoma brucei gambiense Human African Trypanosomiasis

Author(s) -

François Chappuis,

N. Udayraj,

K. Stietenroth,

A. Meussen,

Patrick Bovier

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/432576

Subject(s) - eflornithine , african trypanosomiasis , medicine , trypanosoma brucei , trypanosomiasis , adverse effect , virology , biology , biochemistry , gene , enzyme , spermidine

Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kiri, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with melarsoprol in 2001 and 2002 (n = 708).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research